Treats cardiac decompensation due to depressed contractility. ANDA 74277, held by Hikma. Dobutamine Hydrochloride.
As of Nov 16, 2026, ANDA 74277 (Dobutamine Hydrochloride), held by Hikma, was first approved by FDA on Oct 31, 1994, with 9 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short‑term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 1994 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dobutamine HydrochlorideEQ 12.5MG BASE/ML · injectable;injection | Dobutamine Hydrochloride | Rx |
| Mar 6, 2024 | Supplement 21Labeling · Standard review | Approved | None posted |
| Nov 7, 2001 | Supplement 13Labeling | Approved | None posted |
| Apr 3, 2001 | Supplement 12Manufacturing | Approved | None posted |
| Mar 5, 2001 | Supplement 11Manufacturing | Approved | None posted |
| Jul 20, 1998 | Supplement 10Labeling | Approved | None posted |
| Dec 22, 1997 | Supplement 9Labeling | Approved | None posted |
| Feb 26, 1997 | Supplement 3Labeling | Approved | None posted |
| Aug 28, 1996 | Supplement 6Manufacturing | Approved | None posted |
| Aug 28, 1996 | Supplement 7Manufacturing | Approved | None posted |
| Oct 31, 1994 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters